Satoshi Konagai
Director/Board Member at Solu Therapeutics
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Amy Burroughs | F | 54 |
Cleave Therapeutics, Inc.
 Cleave Therapeutics, Inc. BiotechnologyHealth Technology Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA. | 5 years |
| Brandon Turunen | M | - |
Solu Therapeutics
 Solu Therapeutics Pharmaceuticals: MajorHealth Technology Solu Therapeutics is an American precision-medicine company focused on developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The company is located in the US. The company's proprietary cytotoxicity targeting chimera (cytac) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets, providing the capability to develop next-generation medicines that harness the power of biologics with the vast target binding space of small molecules. | - |
| Philip Vickers | M | 64 |
Solu Therapeutics
Solu Therapeutics Pharmaceuticals: MajorHealth Technology Solu Therapeutics is an American precision-medicine company focused on developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The company is located in the US. The company's proprietary cytotoxicity targeting chimera (cytac) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets, providing the capability to develop next-generation medicines that harness the power of biologics with the vast target binding space of small molecules. | - |
| John Pribis | M | - |
Solu Therapeutics
Solu Therapeutics Pharmaceuticals: MajorHealth Technology Solu Therapeutics is an American precision-medicine company focused on developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The company is located in the US. The company's proprietary cytotoxicity targeting chimera (cytac) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets, providing the capability to develop next-generation medicines that harness the power of biologics with the vast target binding space of small molecules. | - |
| Hiroshi Kawabe | M | 72 | 5 years | |
| Tatsuro Ishizuka | M | 68 | 5 years | |
| Mamoru Sekiyama | M | 74 | 7 years | |
| Noriyuki Uematsu | M | 64 | 8 years | |
| Peter Thompson | M | 64 |
Cleave Therapeutics, Inc.
Cleave Therapeutics, Inc. BiotechnologyHealth Technology Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA. | 14 years |
| Omar Khalil | M | - |
Solu Therapeutics
Solu Therapeutics Pharmaceuticals: MajorHealth Technology Solu Therapeutics is an American precision-medicine company focused on developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The company is located in the US. The company's proprietary cytotoxicity targeting chimera (cytac) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets, providing the capability to develop next-generation medicines that harness the power of biologics with the vast target binding space of small molecules. | 1 years |
| Laura Shawver | M | 66 |
Cleave Therapeutics, Inc.
Cleave Therapeutics, Inc. BiotechnologyHealth Technology Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA. | 5 years |
| Chihiro Suematsu | M | 68 |
Kyoto University
| 23 years |
| John Diekman | M | 81 |
Cleave Therapeutics, Inc.
Cleave Therapeutics, Inc. BiotechnologyHealth Technology Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA. | - |
| Haruko Shibumura | F | 59 | 5 years | |
| Claudia Mitchell | M | - | 5 years | |
| Hiroo Sasaki | M | 68 | 6 years | |
| Ryosuke Munakata | M | - | 9 years | |
| Tadayoshi Hirata | M | - |
Astellas Venture Management LLC
 Astellas Venture Management LLC Investment ManagersFinance Astellas Venture Management LLC (Astellas Venture Management) is a venture capital subsidiary of Astellas Pharma Inc founded in 2000. The firm is headquartered in San Francisco, California. | 6 years |
| Christoph Westphal | M | 56 |
Solu Therapeutics
Solu Therapeutics Pharmaceuticals: MajorHealth Technology Solu Therapeutics is an American precision-medicine company focused on developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The company is located in the US. The company's proprietary cytotoxicity targeting chimera (cytac) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets, providing the capability to develop next-generation medicines that harness the power of biologics with the vast target binding space of small molecules. | - |
| John Hamer | M | 66 |
Solu Therapeutics
Solu Therapeutics Pharmaceuticals: MajorHealth Technology Solu Therapeutics is an American precision-medicine company focused on developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The company is located in the US. The company's proprietary cytotoxicity targeting chimera (cytac) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets, providing the capability to develop next-generation medicines that harness the power of biologics with the vast target binding space of small molecules. | - |
| SUMIHO NAKATSU | F | - | 7 years | |
| Peter Hutt | M | 89 |
Solu Therapeutics
Solu Therapeutics Pharmaceuticals: MajorHealth Technology Solu Therapeutics is an American precision-medicine company focused on developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The company is located in the US. The company's proprietary cytotoxicity targeting chimera (cytac) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets, providing the capability to develop next-generation medicines that harness the power of biologics with the vast target binding space of small molecules. | - |
| Hideaki Matsuoka | M | - |
Astellas Venture Management LLC
Astellas Venture Management LLC Investment ManagersFinance Astellas Venture Management LLC (Astellas Venture Management) is a venture capital subsidiary of Astellas Pharma Inc founded in 2000. The firm is headquartered in San Francisco, California. | - |
| Jon Root | M | 64 |
Cleave Therapeutics, Inc.
Cleave Therapeutics, Inc. BiotechnologyHealth Technology Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Hikaru Saito | M | - |
Astellas Venture Management LLC
Astellas Venture Management LLC Investment ManagersFinance Astellas Venture Management LLC (Astellas Venture Management) is a venture capital subsidiary of Astellas Pharma Inc founded in 2000. The firm is headquartered in San Francisco, California.
Cleave Therapeutics, Inc.
Cleave Therapeutics, Inc. BiotechnologyHealth Technology Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA. | 7 years |
| Sef P. Kurstjens | M | 60 | 8 years | |
| Keiko Yamagami | F | 63 | - | |
| Gen Xie | M | 57 |
Kyoto University
| 6 years |
| Yoshiharu Aizawa | M | 78 | - | |
| Yoshinori Ehara | M | 50 |
Kyoto University
| 6 years |
| Jin Kanamori | M | 69 | - | |
| Yukihiko Sato | M | - | - | |
| Kamiya Yuki | M | - |
Kyoto University
| 6 years |
| Akihiro Hatanaka | M | 49 |
Kyoto University
| 6 years |
| Masahiro Ueda | M | - |
Kyoto University
| 4 years |
| Qingwei Sun | M | 41 |
Kyoto University
| 4 years |
| Michael Rafa | M | - | - | |
| Kazuki Notsu | M | - |
Kyoto University
| 4 years |
| Masato Tsumamoto | M | 41 |
Kyoto University
| 4 years |
| Jeffrey Ludwig | M | 58 | 1 years | |
| Dadan Kusdiana | M | 55 |
Kyoto University
| 3 years |
| Tsutomu Nanisho | M | - |
Kyoto University
| 3 years |
| Hiroki Tanaka | M | - |
Kyoto University
| 4 years |
| Nonomura Kazuhiko | M | - |
Kyoto University
| 6 years |
| Kengo Tanaka | M | - |
Kyoto University
| 4 years |
| Shinya Oka | M | 39 |
Kyoto University
| 4 years |
| Kazunori Maruyama | M | - |
Astellas Venture Management LLC
Astellas Venture Management LLC Investment ManagersFinance Astellas Venture Management LLC (Astellas Venture Management) is a venture capital subsidiary of Astellas Pharma Inc founded in 2000. The firm is headquartered in San Francisco, California. | 19 years |
| Anita Firmant Eko Susetyowati | M | 64 |
Kyoto University
| 3 years |
| Xiao Hang Yuan | M | - |
Kyoto University
| - |
| Masanori Miyanishi | M | - |
Kyoto University
| 3 years |
| Hiroshi Takishita | M | 48 |
Kyoto University
| 2 years |
| Kazuo Okushima | M | - |
Kyoto University
| 4 years |
| Xin Zhou | F | 43 |
Kyoto University
| 4 years |
| Masafumi Nogimori | M | 76 | 11 years | |
| Masaaki Usui | M | - | - | |
| Yuta Yamamoto | M | 41 |
Kyoto University
| 4 years |
| Sho Kawano | M | - |
Kyoto University
| 4 years |
| Hiromichi Kimura | M | 73 | 4 years | |
| Linda Friedman | F | - | - | |
| Claire Thomas | M | 68 | 3 years | |
| Yosuke Tsuji | M | 48 |
Kyoto University
| 4 years |
| Fumi Shiba | F | - |
Kyoto University
| 4 years |
| Bernhardt Zeiher | M | 60 | 4 years | |
| Yasushi Shimizu | M | 49 |
Kyoto University
| 4 years |
| Shusuke Nagai | M | 43 |
Kyoto University
| 4 years |
| Shintaro Hanatani | M | 48 |
Kyoto University
| 1 years |
| Chihiro Hosoya | F | - | 8 years | |
| Zuo Hao Hu | M | 60 |
Kyoto University
| 5 years |
| Keita Matsuura | M | 44 |
Kyoto University
| 3 years |
| Ling Fei Ma | M | 65 |
Kyoto University
| 3 years |
| Stig Ogata | M | - | - | |
| Hiroaki Ohta | M | 47 |
Kyoto University
| 3 years |
| Masahiko Maekawa | M | 46 |
Kyoto University
| 4 years |
| Takeshi Hayami | M | 47 |
Kyoto University
| 4 years |
| Anita Firmanti | F | 64 |
Kyoto University
| 3 years |
| Makoto Fujishima | M | 66 |
Kyoto University
| 3 years |
| Hiroshi Tanaka | M | - |
Kyoto University
| 6 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Japan | 62 | 80.52% |
| United States | 16 | 20.78% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Satoshi Konagai
- Personal Network
